Rabies immunoglobulin
Clinical data | |
---|---|
Trade names | Imogam Rabies-HT, Kedrab, Hyperrab, others |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intramuscular injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
ChemSpider |
|
UNII |
Rabies immunoglobulin (RIG) is a medication made up of
Common side effects include pain at the site of injection, fever, and headache.
The use of rabies immunoglobulin in the form of blood serum dates from 1891.
Medical uses
Rabies immunoglobulin (RIG) is indicated for the passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and in combination with a rabies vaccine.[18][19][1]
Society and culture
Names
There are three versions of rabies immunoglobulin licensed and available in the US.[20] Imogam Rabies-HT is produced by Sanofi Pasteur.[6] Kedrab is produced by Kedrion Biopharma.[18][7] Hyperrab is produced by Grifols.[8]
Imogam Rabies-HT and Kedrab have a nominal potency of 150 IU/mL while Hyperrab has a nominal potency of 300 IU/mL and requires smaller dosing. All three versions are used for post-exposure[21] and indicate local infusion at the wound site with additional amount intramuscularly at a site distant from vaccine administration.[22]
Kamrab is approved for medical use in Australia.[1]
References
- ^ a b c d "Kamrab". Therapeutic Goods Administration (TGA). 23 August 2021. Retrieved 10 September 2021.
- ^ "Kamrab PI". Health Canada. 25 April 2012. Retrieved 10 September 2021.
- ^ "Imogam PI". Health Canada. 25 April 2012. Retrieved 10 September 2021.
- ^ "Hyperrab S/D PI". Health Canada. 25 April 2012. Retrieved 10 September 2021.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ a b "Imogam Rabies-HT - human rabies virus immune globulin injection, solution". DailyMed. Retrieved 24 March 2020.
- ^ a b "Kedrab- human rabies virus immune globulin injection, solution". DailyMed. Retrieved 24 March 2020.
- ^ a b "Hyperrab (rabies immune globulin- human injection, solution". DailyMed. Retrieved 24 March 2020.
- ^ "Hyperrab S/D (rabies immune globulin- human injection". DailyMed. Retrieved 10 September 2021.
- ^ a b c d e f g h i "Rabies Immune Globulin". The American Society of Health-System Pharmacists. Archived from the original on 18 March 2011. Retrieved 8 January 2017.
- ISBN 9789241547659.
- ISBN 9780857111562.
- ISBN 978-1455700905. Archivedfrom the original on 9 January 2017.
- ^ ISBN 9781550092257. Archivedfrom the original on 9 January 2017.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ISBN 978-0-07-148480-0.
- ^ ISBN 9780123870414. Archivedfrom the original on 9 January 2017.
- ^ a b "Kedrab". U.S. Food and Drug Administration (FDA). 21 March 2018. Retrieved 7 June 2020. This article incorporates text from this source, which is in the public domain.
- FDA. 23 August 2017.
- ^ "Vaccine and Immune Globulin Availability". Centers for Disease Control and Prevention (CDC). 26 February 2020. Retrieved 24 March 2020.
- ^ "WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans" (PDF). World Health Organization (WHO). 2014.
- ^ "Rabies Biologics | Specific Groups | CDC". www.cdc.gov. 15 January 2021. Retrieved 18 November 2022.
Further reading
- Meeting of the Antimicrobial Drugs Advisory Committee (PDF) (Briefing Document). U.S. Food and Drug Administration (FDA). 25 April 2019.